The Impact of TRIPS on Global Intellectual Property Rights

When the World Trade Organization’s Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement came into force on January 1, 1995, it fundamentally reshaped how intellectual property is governed across the globe. For the first time, IP protections – covering everything from patents and trademarks to copyrights and trade secrets – became binding international obligations tied directly to global trade. For developed nations, this was largely a formalization of existing standards. For developing and least-developed countries, it marked the beginning of a long and often difficult process of legal and institutional transformation.

What is TRIPS and where did it come from? 🔗

TRIPS emerged from the Uruguay Round of trade negotiations (1986-1994), a period when developed countries – particularly the United States and European nations – pushed hard to bring intellectual property into the international trade framework. The impetus was largely driven by powerful industries in the developed world, particularly pharmaceutical, software, and entertainment companies, that wanted stronger and more enforceable global IP protections.

TRIPS introduced intellectual property law into the multilateral trading system for the first time and remains the most comprehensive multilateral agreement on IP to date. It is administered by the WTO and applies to all WTO member states as part of a “single undertaking” – meaning no country can pick and choose which WTO agreements to follow. Joining the WTO means accepting TRIPS in full.

The agreement establishes minimum standards for seven categories of intellectual property: copyrights, trademarks, geographical indications, industrial designs, patents, integrated circuit layout designs, and undisclosed information (trade secrets). It also sets out enforcement procedures and a dispute settlement mechanism, giving it considerably more teeth than previous IP conventions.

How TRIPS reshaped global patent law 🔗

One of TRIPS’ most consequential provisions concerns patents. Under the agreement, WTO members must make patents available for inventions in all fields of technology, provided standard criteria of novelty, inventiveness, and industrial applicability are met. Patent protection must last at least 20 years from the date of filing. This was a significant departure for many countries – particularly in Asia and Latin America – that had previously excluded sectors like pharmaceuticals and food from patent eligibility as a matter of deliberate industrial policy.

Before TRIPS, countries had considerable latitude to design patent laws that suited their development needs. India, for instance, did not allow product patents for medicines under its 1970 Patents Act, enabling a thriving domestic generic pharmaceutical industry. TRIPS required India and similar countries to overhaul these laws entirely. Low and middle-income countries who were net buyers of technology feared that stronger IP protection at home would increase profit flows to foreign patent holders, and their resistance during negotiations was substantial – though ultimately unsuccessful.

Standardization versus flexibility 🔗

TRIPS is often described as a minimum standards agreement. Members are free to provide more extensive IP protection if they wish, and they are left to determine the appropriate method of implementing TRIPS within their own legal systems. This design allows some flexibility in how countries comply, but it does not change the baseline obligations they must meet. In practice, many developing countries found themselves copying developed-country IP legislation wholesale, often because they lacked the technical expertise to craft laws that strategically used every available TRIPS flexibility. As critics like Cory Doctorow have noted, this reliance on external technical assistance sometimes pushed countries toward implementing stronger IP monopolies than TRIPS actually required.

The unequal burden on developing countries 🔗

The challenges of TRIPS compliance were never evenly distributed. Developed countries, with their established legal infrastructure and well-funded enforcement systems, adapted relatively smoothly. For developing and least-developed countries, the picture was very different.

Developed countries were required to implement TRIPS fully by January 1, 1996. Developing countries had until January 1, 2000, and least-developed countries were originally given until January 1, 2006, with subsequent extensions. Countries that lacked pharmaceutical patent protection were given extra time in that specific area. These staggered timelines acknowledged the disparity in institutional capacity, but they did not eliminate the fundamental pressure to restructure domestic law in ways that may not have served national development interests.

The costs were not merely administrative. Implementing TRIPS requires significant improvement, adaptation, and enlargement of legal, administrative, and enforcement frameworks, as well as human resource development – tasks that are demanding even for well-resourced governments. For smaller and poorer countries, building an effective IP system from the ground up while simultaneously addressing more pressing social needs created real institutional strain.

Most developing and least-developed countries tend to be hampered by a shortage of resources, weak intellectual property infrastructure, lack of skilled personnel, and inadequate awareness of the various IP treaties and conventions. This has meant that the promise of TRIPS – that stronger IP protection would stimulate technology transfer and innovation – has not materialized equally for all members.

The pharmaceutical patent problem 🔗

Nowhere has the tension between TRIPS obligations and development needs been sharper than in pharmaceuticals. Strong patent protection raises the prices of medicines by granting patent holders exclusive rights for 20 years, effectively blocking the production of cheaper generic alternatives. For countries where a large share of the population cannot afford brand-name drugs, this has had direct public health consequences.

Many argue that IP rights do little to stimulate innovation in developing countries and instead require them to spend limited resources on creating and enforcing IP rules in the face of more important social issues. The debate intensified as the HIV/AIDS crisis swept through sub-Saharan Africa in the late 1990s, where life-saving antiretroviral drugs were patented and priced far beyond the reach of governments and patients.

The Doha Declaration: a critical turning point 🔗

Pressure from developing countries and civil society led to a landmark moment at the WTO Ministerial Conference in Doha in November 2001, where members adopted a separate Declaration on TRIPS and Public Health. The Doha Declaration affirmed that the TRIPS Agreement does not and should not prevent members from taking measures to protect public health, and that the agreement should be interpreted to support access to medicines for all.

Crucially, the Declaration clarified that each member has the right to grant compulsory licences and the freedom to determine the grounds on which those licences are granted. Compulsory licensing allows a government to authorize the production or import of a patented medicine without the patent holder’s consent, typically in exchange for payment of a royalty. Public health crises – including HIV/AIDS, tuberculosis, and malaria – were recognized as grounds that could justify compulsory licensing.

The Declaration also extended pharmaceutical patent exemptions for least-developed countries. The 2001 Doha Declaration stressed the need for TRIPS to be part of wider action to address public health problems afflicting developing economies, and it led to a formal legal amendment to the agreement – Article 31bis – which created a special mechanism allowing countries with sufficient manufacturing capacity to produce generic medicines under compulsory license specifically for export to countries that cannot manufacture medicines themselves. This amendment entered into force in 2017.

COVID-19 and renewed debates 🔗

The COVID-19 pandemic brought TRIPS back into sharp international focus. In October 2020, India and South Africa submitted a proposal to the TRIPS Council calling for a partial suspension of the agreement to accelerate access to COVID-19 vaccines, diagnostics, and treatments. The June 2022 WTO Ministerial Conference adopted a Decision on the TRIPS Agreement that clarified the scope for domestic measures to override patent rights in a health emergency, and provided a flexible mechanism for production of COVID-19 vaccines for export. However, the decision fell short of the broader waiver that many developing countries had requested, and negotiations on extending it to COVID-19 therapeutics and diagnostics stalled.

Aligning domestic laws with TRIPS: ongoing challenges 🔗

Beyond public health, the broader challenge of aligning national legal systems with TRIPS requirements continues. Many countries have had to introduce entirely new categories of IP law, train judges and administrative officials, establish customs enforcement mechanisms, and create judicial remedies for IP violations – all while balancing these new obligations against other pressing development priorities.

TRIPS sought to construct a uniform system of IP protection to support a global market for trade in technology goods – but this approach did not take into account where particular countries were in their national development trajectory. The result is a system that has worked well for technology-exporting nations but placed significant compliance costs on technology-importing ones.

There has also been pressure beyond TRIPS itself. Many bilateral and regional trade agreements – often negotiated with the United States or the European Union – include TRIPS-Plus provisions that go beyond the WTO’s minimum standards. These TRIPS-Plus standards can take many forms, including stricter enforcement, longer patent terms, and anti-circumvention laws for digital rights management. For developing countries that negotiated flexibilities into TRIPS, these bilateral pressures represent a separate challenge to preserving policy space.

TRIPS and foreign direct investment 🔗

Not all assessments of TRIPS are negative for developing countries. There is evidence that stronger IP protection, as required by TRIPS, has attracted foreign direct investment. Enforcement of the TRIPS agreement constitutes a driving force of FDI in host countries, according to research covering 23 developing countries between 1985 and 2012. Countries such as Brazil, China, Thailand, and India strengthened their IP protection measures to comply with TRIPS, and this alignment with international standards has helped signal credibility to foreign investors.

Additionally, research on India’s pharmaceutical sector found that TRIPS compliance had a positive effect on research and development expenditure among Indian pharmaceutical firms. This suggests that stronger IP protection, while restrictive in some respects, can also push domestic industry to invest more in innovation rather than relying on reverse engineering.

The debate over reform 🔗

Three decades after its introduction, TRIPS remains a contested framework. Nobel laureate Joseph Stiglitz argued that TRIPS imposed on the entire world the dominant IP regime of the United States and Europe – and that this regime is not in the interest of developing countries. Others argue that TRIPS provides a necessary international baseline without which IP rights in global trade would be chaotic and unenforceable.

Reform advocates largely center their arguments around three areas: expanding public health flexibilities, reducing the compliance burden on least-developed countries, and bringing TRIPS up to date with the digital economy. Modern challenges – including access to medicines, compulsory licensing, and the digital revolution – continue to shape global IP law and trade policy, making TRIPS reform a central issue in global economic governance. TRIPS was largely drafted before the widespread commercialization of the internet, meaning its provisions on software, digital content, and e-commerce have had to be interpreted and stretched to cover realities that were not envisaged during the Uruguay Round.

The tension at the heart of TRIPS has never been fully resolved: it is simultaneously a framework for protecting the economic interests of those who create and own intellectual property, and a set of obligations that can limit the ability of poorer countries to access technology, medicines, and knowledge on affordable terms. How that tension is managed – through the agreement’s existing flexibilities, through amendments, or through broader reform – will continue to shape the relationship between global trade and development for years to come.

What do you think? Does the TRIPS agreement strike the right balance between protecting the rights of innovators and ensuring that developing countries can access essential technologies and medicines? And given that TRIPS was designed before the digital economy truly took off, should it be fundamentally renegotiated to reflect the realities of 21st-century global trade?

References

1. https://www.wto.org/english/tratop_e/trips_e/intel2_e.htm
2. https://www.wto.org/english/docs_e/legal_e/27-trips_01_e.htm
3. https://en.wikipedia.org/wiki/TRIPS_Agreement
4. https://pmc.ncbi.nlm.nih.gov/articles/PMC7549422/
5. https://www.uspto.gov/ip-policy/patent-policy/trade-related-aspects-ip-rights
6. https://unctad.org/system/files/official-document/ite1_en.pdf
7. https://open.mitchellhamline.edu/cgi/viewcontent.cgi?article=1079&context=cybaris
8. https://pmc.ncbi.nlm.nih.gov/articles/PMC10726804/
9. https://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_trips_e.htm
10. https://www.wto.org/english/tratop_e/trips_e/public_health_faq_e.htm
11. https://www.wto.org/english/tratop_e/trips_e/pharmpatent_e.htm
12. https://www.eff.org/issues/trips
13. https://www.sciencedirect.com/science/article/abs/pii/S0313592615300400
14. https://www.upcounsel.com/trips-patent